Skip to main content

Advertisement

SpringerLink
Log in

CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients

  • Original Article
  • Published:
Tumor Biology

Abstract

Chemokine C-X-C motif ligand 5 (CXCL5) is critical for bladder cancer growth and progression. Our previous study demonstrated that increase of CXCL5 in bladder cancer cell lines had an effect on tumor growth and progression. This study aims to investigate the expression of CXCL5 in tissue and urine of bladder cancer patients, in relation to clinicopathologic parameters, and as a predictive value in diagnosing and evaluating bladder cancer. Urothelial bladder cancer tissues from 255 patients were profiled for CXCL5 alterations by immunohistochemistry. Urine samples collected from patients with bladder cancer and urinary tract infections as well as healthy volunteers were analyzed by ELISA. High expression of CXCL5 in bladder cancer tissue was correlated with TNM stage (P = 0.012), cancer grade (P = 0.001), and lymph node metastasis (P = 0.007). CXCL5 alterations were associated with overall survival (P = 0.007), progression free survival (P = 0.004), and recurrence free survival in muscle invasive bladder cancers (P = 0.026). CXCL5 expression in the urine of bladder cancer patients was significantly different from urinary tract infection patients (P = 0.001) and healthy volunteers. However, urine leukocytes may predict CXCL5 levels (β = 0.56, P < 0.001, R 2 = 0.314). CXCL5 expression in urine was also related to bladder cancer TNM stage (P = 0.039), lymph node metastasis (P = 0.023), tumor size (P = 0.007), and tumor grade (P = 0.005). The sensitivity and specificity for CXCL5/creatinine in predicting bladder cancer were 80.4 and 61.3 %, respectively. These results suggest increased CXCL5 expression in cancer tissue predicts poor survival in bladder cancer patients. CXCL5 expression in urine is useful in a minimally invasive modality for bladder cancer diagnosis. However, urine leukocytes are significant predictors of CXCL5 levels and may affect its result in bladder cancer diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Rebecca LS, Kimberly DM, Ahmedin J. Cancer statistics. CA Cancer J Clin. 2015;65:5–29.

    Article  Google Scholar 

  2. Saurabh C, Freddie B, Joannie L, et al. International variations in bladder cancer incidence and mortality. Eur Urol. 2014;66:1059–73.

    Google Scholar 

  3. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003;21:690–6.

    Article  PubMed  Google Scholar 

  4. Alexandra L, Marta R, Francisco R, et al. Inflammatory biomarkers and bladder cancer prognosis: a systematic review. Eur Urol. 2014;66:1078–91.

    Article  Google Scholar 

  5. Mantovani A. Cancer: inflaming metastasis. Nature. 2009;457:36–7.

    Article  CAS  PubMed  Google Scholar 

  6. Zheng JJ, Zhu X, Zhang J. CXCL5 knockdown expression inhibits human bladder cancer T24 cells proliferation and migration. Biochem Biophys Res Commun. 2014;446:18–24.

    Article  CAS  PubMed  Google Scholar 

  7. Krajewsha M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancers. Am J Pathol. 1996;148:1567–76.

    Google Scholar 

  8. Liu S, Sun Q, Wang F, et al. Arsenic induced overexpression of inflammatory cytokines based on the human urothelial cell model in vitro and urinary secretion of individuals chronically exposed to arsenic. Chem Res Toxicol. 2014;27:1934–42.

    Article  CAS  PubMed  Google Scholar 

  9. Kim WJ, Kim EJ, Kim SK, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9:3–12.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lv S, Turlova E, Zhao S, et al. Prognostic and clinicopathological significance of surviving expression in bladder cancer patients: a meta-analysis. Tumor Biol. 2014;35:1565–74.

    Article  CAS  Google Scholar 

  11. Habuchi T, Marberger M, Droller MJ, et al. Prognostic markers for bladder cancer: international consensus panel on bladder tumor markers. Urology. 2005;66:64–74.

    Article  PubMed  Google Scholar 

  12. Xylinas E, Kluth LA, Rieken M, et al. Urine markers for detection and surveillance of bladder cancer. Urol Oncol. 2014;32:222–9.

    Article  CAS  PubMed  Google Scholar 

  13. Qiu Y, Zhu J, Bandi V, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168:968–75.

    Article  PubMed  Google Scholar 

  14. Masson-Lecomte A, Rava M, Real FX, et al. Inflammatory biomarkers and bladder cancer prognosis: a systematic review. Eur Urol. 2014;66:1078–91.

    Article  CAS  PubMed  Google Scholar 

  15. Keeley EC, Mehrad B, Strieter RM. CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res. 2010;106:91–111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Viola A, Sarukhan A, Bronte V, et al. The pros and cons of chemokines in tumor immunology. Trends Immunol. 2012;33:496–504.

    Article  CAS  PubMed  Google Scholar 

  17. Kowalczuk O, Burzykowski T, Niklinska WE, et al. CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. Tumor Biol. 2014;35:4619–28.

    Article  CAS  Google Scholar 

  18. Park JY, Park KH, Bang S, et al. CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol. 2007;133:835–40.

    Article  CAS  PubMed  Google Scholar 

  19. Li AH, King J, Moro A, et al. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol. 2011;178:1340–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Karagiannis GS, Saraon P, Jarvi KA, et al. Proteomic signatures of angiogenesis in androgen-independent prostate cancer. Prostate. 2014;74:260–72.

    Article  CAS  PubMed  Google Scholar 

  21. Zhou SL, Dai Z, Zhou ZJ, et al. CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils. Carcinogenesis. 2014;35:597–605.

    Article  CAS  PubMed  Google Scholar 

  22. Zhou SL, Dai Z, Zhou ZJ, et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology. 2012;56:2242–54.

    Article  CAS  PubMed  Google Scholar 

  23. Sexton WJ, Wiegand LR, Correa JJ, et al. Bladder cancer: a review of non-muscle invasive disease. Cancer Control. 2010;17:256–68.

    PubMed  Google Scholar 

  24. Günther JH, Jurczok A, Wulf T, et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res. 1999;59:2834–7.

    PubMed  Google Scholar 

  25. Lim JB, Chung HW. Serum ENA78/CXCL5, SDF-1/CXCL12, and their combinations as potential biomarkers for prediction of the presence and distant metastasis of primary gastric cancer. Cytokine. 2015;73:16–22.

    Article  CAS  PubMed  Google Scholar 

  26. Zhou SL, Zhou ZJ, Hu ZQ, et al. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling. Cancer Lett. 2015;358:124–35.

    Article  CAS  PubMed  Google Scholar 

  27. Wang JW, Zhang XD, Wei P, et al. Livin, survivin and caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer. World J Urol. 2014;32:1477–84.

    Article  CAS  PubMed  Google Scholar 

  28. Wang LJ, Feng CC, Ding GX, et al. Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer. Tumor Biol. 2014;35:2989–95.

    Article  CAS  Google Scholar 

  29. Guo GY, Xu YY, Gong MC, et al. USP28 is a potential prognostic marker for bladder cancer. Tumor Biol. 2014;35:4017–22.

    Article  CAS  Google Scholar 

  30. Mowatt G, Zhu S, Kilonzo M, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess. 2010;14:1–331.

    Article  CAS  Google Scholar 

  31. Trikha M, Corringham R, Klein B, et al. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9:4653–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Coffelt SB, Kersten K, Doornebal CW, et al. IL-17-producing cd T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015. doi:10.1038/nature14282.

    PubMed  PubMed Central  Google Scholar 

  33. Gakis G. The role of inflammation in bladder cancer. Adv Exp Med Biol. 2014;816:183–96.

    Article  CAS  PubMed  Google Scholar 

  34. Qiu Y, Zhu J, Bandi V, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168:968–75.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Friendship Hospital Affiliated to Capital Medical University, 95th Yong An Road, Xuan Wu District, Beijing, China, 100050

    Xi Zhu, Wenying Wang, Hongliang Shen, Yi Lu, Gangyue Hao & Ye Tian

  2. Department of Clinical Laboratory, Peking University Third Hospital, Beijing, China

    Yan Qiao & Jiajia Zheng

  3. Department of Pathology, Friendship Hospital Affiliated to Capital Medical University, Beijing, China

    Weihua Liu

Authors
  1. Xi Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Qiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weihua Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hongliang Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yi Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gangyue Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jiajia Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ye Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ye Tian.

Ethics declarations

Funding information

This study was funded by the National Nature Science Foundation of China (61401290) and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201604).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, X., Qiao, Y., Liu, W. et al. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients. Tumor Biol. 37, 4569–4577 (2016). https://doi.org/10.1007/s13277-015-4275-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4275-4

Keywords

Search

Navigation